Downsizing and purchases of psychotropic drugs: A longitudinal study of stayers, changers and unemployed Authors: Sandra Blomqvist, Kristina Alexanderson, Jussi Vahtera, Hugo Westerlund, Linda L. Magnusson Hanson, Ali B. Mahmoud, Ali B. Mahmoud, Ali B. Mahmoud, Ali B. Mahmoud Published: 2023 ABSTRACT BackgroundThe evidence is insufficient regarding the association between organizational downsizing and employee mental health. Our aim was to analyze trajectories of prescribed sedatives and anxiolytics with a sufficiently long follow-up time to capture anticipation, implementation and adaption to a downsizing event among stayers, changers and those who become unemployed compared to unexposed employees.MethodResidents in Sweden aged 20–54 years in 2007, with stable employment between 2004 and 2007, were followed between 2005 and 2013 (n = 2,305,795). Employment at a workplace with staff reductions ≥18% between two subsequent years in 2007–2011 (n = 915,461) indicated exposure to, and timing of, downsizing. The unexposed (n = 1,390,334) were randomized into four corresponding sub-cohorts. With generalized estimating equations, we calculated the odds ratios (OR) of purchasing prescribed anxiolytics or sedatives within nine 12-month periods, from four years before to four years after downsizing. In order to investigate whether the groups changed their probability of purchases over time, odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated contrasting the prevalence of purchases during the first and the last 12-month period within four time periods for each exposure group.ResultsThe odds of purchasing psychotropic drugs increased more for changers (sedatives OR 1.08, 95% CI 1.05–1.11) and unemployed (anxiolytics OR 1.08, 95% CI 1.03–1.14), compared to unexposed before downsizing, while for stayers purchases increased more than for unexposed during and after downsizing. Among those without previous sickness absence, stayers increased their purchases of psychotropic drugs from the year before the event up to four years after the event.ConclusionThis study indicates that being exposed to downsizing is associated with increased use of sedatives and anxiolytics, before the event among those who leave, but especially thereafter for employees who stay in the organization. Introduction Downsizings has become a common aspect of working life today, but may be associated with negative health consequences [1]. According to previous research, the negative health consequences of downsizing may be attributed to job insecurity [2, 3], and in the case of job loss, loss of income, social support contact with colleagues and/or social status could be the underlying factors of poor health [4, 5]. For those remaining within the organizations increased workload after the downsizing event [6, 7] and guilt over the dismissal of co-workers, are often put forward as explanations [8]. So far, most studies on downsizing and mental health have used self-reported measures on either exposure, outcome or both [2]. To the best of our knowledge only two studies have used more objective measures of downsizing and mental health comparing survivors and those who lost or left their job to unexposed workers [9, 10]. A Finish study on municipal employees [9] found that men who lost/left their jobs and men and women who stayed in an organization after downsizing had higher rates of purchasing psychotropic drugs compared to the unexposed. In our own previous work, we found that the odds of purchasing prescribed antidepressants increased more during and after the downsizing for exposed workers without prior health problems than for unexposed workers [10]. People with prior health problems and unemployment following downsizing increased their purchases of antidepressants before the event. This indicates that it is imperative to study people’s health across a relatively long time window and account for possible health selection. Still, the evidence is insufficient regarding the association between organizational downsizing and employee mental health due to cross sectional designs and the large heterogeneity of measures, sample and designs in previous studies [11]. Findings have been inconclusive, especially for survivors [5, 9, 12]. In the previous research there has also been a strong focus on depression while less is known about how downsizing affect other mental health problems such as anxiety or sleep disturbances. Within this prospective register-based cohort study we aimed to analyze trajectories of prescribed sedatives and anxiolytics for employees exposed to downsizing, i.e. stayers, changers and those who become unemployed after downsizing, compared to unexposed employees. Because anxiety and sleeping problems have been found to precede the onset of depression [13–16], we hypothesized that downsizing may increase purchases of anxiolytics and sedatives in an earlier stage than in purchases of antidepressants. We first aimed to examine whether downsizing increases purchases of sedatives and anxiolytic drugs and second, given that they already purchased these types of drugs during the study period we aimed to examine whether downsizing was associated with increased numbers of purchases of these drugs, which may indicate an increased severity of symptoms. The present study is the correct version of a previously published version of this paper, now retracted, in which we found errors due to a coding mistake [17, 18]. That version had erroneously classified some employees as stayers, when they in fact had changed employer the year following downsizing. The error arose due to a mistake of relying on workplace, rather than individual, level information when classifying the employees’ post-downsizing status. The corrected version therefore has a larger proportion of changers, a smaller proportion of stayers, while the unemployed remain unaffected by our error. Consequently, the results for the changers became more stable after the correction. Syntaxes and results have been carefully checked, cross-checked with proportions in public administrative data, and validated by studying expected changes in a randomly chosen, large company. Materials and methods Study population The study population was drawn from the Longitudinal integration database for health insurance and labor market studies (LISA), administered by Statistics Sweden, including all people aged 16 to 64 years and living in Sweden on December 31, 2004 (n = 5,750,279). Our analytical sample contained those who lived in Sweden between 31 December 2004 and 31 December 2013, were gainfully employed (i.e., with income from work above a specific amount) each year between 2004 and 2007, employed according to their primary occupation the year before they were exposed to downsizing and aged 20 to 54 years in 2007, i.e., those who had entered the labor market and were not about to retire. Information from the Swedish National Prescribed Drug Register and Statistics on Dynamics of Enterprises and Establishments (DEE) was obtained by linkage through the Swedish personal identity number but de-identified by Statistics Sweden before delivery of data and used to determine exposure to downsizing. People working in an establishment that was not registered in DEE, were excluded. Those who had been exposed to a downsizing event between November 2006 and November 2007, the year before our period of interest, were excluded to enable us to study new downsizing events. This resulted in a total analytic sample of 2,305,795 individuals, for details see Fig 1. The project has received ethical approval from the Regional Ethical Review Board of Stockholm and the data were analyzed anonymously. Flow chart of study sample, based on information from the Longitudinal integration database for health insurance and labor market studies (LISA) and Statistics on Dynamics of Enterprises and Establishments (DEE). Exposure The Statistics on Dynamics of Enterprises and Establishments (DEE) register provides information on structural changes within establishments and organizations. Through information from the LISA register on main employer, collected annually on 30 November, it was possible to link persons to the DEE register and to assess if a person had been employed at a workplace that went through a major downsizing. In accordance with the most commonly used definition, we classified employees as exposed to major downsizing if they worked at an establishment that reduced their staff by ≥18% between November 2007 and Nov 2008, Nov 2008 and Nov 2009, Nov 2009 and Nov 2010, or Nov 2010 and Nov 2011, respectively [1, 5, 10]. Only new events were examined, i.e., exposure in one 12-month period without exposure in the previous one. Those unexposed to downsizing (n = 1 390 334) were randomly assigned to a cohort with a 12-month period used as unexposed reference and follow-up matching the periods above, to get a suitable comparison group. Employees in the unexposed group had equal probability of being assigned one of the four sub-cohorts. Those exposed to downsizing were grouped into three categories, depending on their employment situation after the downsizing. Those, who have been referred to as survivors in previous literature were divided into two groups; 1) “stayers”, consisting of those who stayed in the same organization the year after the downsizing and 2) “changers”, containing those who remained employed but changed organization after the downsizing. Those who at the end of the year of downsizing were not gainfully employed or had received more than 180 days with unemployment benefits were categorized as “unemployed”. Outcome In this study, purchases of prescribed anxiolytics and sedatives were used as outcomes. Information on drugs was obtained from the Swedish National Prescribed Drug Register covering November 2005 to November 2013. All prescriptions coded N05B (anxiolytics) and N05C (hypnotics and sedatives) according to the Anatomical Therapeutic Chemical classification were extracted from the register with information about date the prescription was filled. This information was used to identify all 12-months periods that a person had purchased prescribed anxiolytics (yes/no) or sedatives (yes/no) during a 9-year time window. We centered the data around the 12-month period a person was exposed to downsizing (year 0) and used available data on annual purchases of prescribed sedatives and anxiolytics from four years before to four years after a downsizing event. These variables were used to investigate if exposure to downsizing increased the likelihood of purchasing sedatives and anxiolytics. The annual numbers of purchases of anxiolytics and sedatives were studied among the users, i.e., those who at any point during our study period had bought anxiolytics or sedatives, to assess the association between downsizing and the amount of purchases. Covariates Annual information on sociodemographic factors that are plausibly associated with downsizing and mental health was retrieved from the LISA register between 2004 and 2013. We controlled for sex, age, educational level, type of living region, and family situation. Men and women tend to work in different sectors that might be associated with different working conditions [19] and gender differences have been observed for depressive symptoms [20]. Furthermore, worrying about losing your job seem to have more detrimental consequences among older employees compared to younger employees [21], and purchases of psychotropic drugs increase with age [22]. Age was categorized into 20–34, 35–49, and 50–59 years, in order to further test for interaction. Low socioeconomic position is associated with higher prevalence of common mental disorders [23] and unemployment is more common among low educated [24]. Educational level was therefore used and categorized into groups: (1) Primary education, (2) Secondary education, (3) Post-secondary education <3 years, and (4) Post-secondary education ≥3 years. Regional differences have been observed in mental health [25] and the consequences of unemployment might be somewhat different in rural areas where new job opportunities often are more limited compared to in bigger cities. Type of living region was coded into three categories depending on the size and density of the population in the municipality where the person lived: (1) Big cities (metropolitan areas, with >90 000 inhabitants within a 30 km radius from the largest municipality center), (2) medium-sized cities (areas with 27 000 to 90 000 inhabitants within a 30 km radius from the largest municipality center, and (3) small cities/villages (areas with <27 000 inhabitants within a 30 km radius from the largest municipality center). Social support has been regarded as a protective factor for both depression and negative health consequences of unemployment [26], while having children may introduce a work to family conflict affecting mental health negatively [27]. Family situation was divided into four different categories: (1) Living with a partner (married, registered partner, or cohabiting) and children, (2) Living with a partner but without children at home, (3) Living with children only and (4) Living alone. We also obtained information about the participants’ pre-downsizing sickness absence history. In Sweden, an employee is generally entitled to sickness absence benefit from the Social Insurance Agency after 14 days with sick pay paid by the employer, if unable to work due to morbidity. We defined previous sickness absence as one day with sickness absence benefit or disability pension during the two years before a downsizing event (meaning at least 15 days of sickness absence). Data analysis To examine the annual prevalence of people with purchases of prescribed sedatives and anxiolytics in the 9-year time window, we applied repeated-measures logistic regression using generalized estimating equations (GEE), which takes into account the intra-individual correlation between measurements. The trajectories were based on 9 observations per person and missing information was handled through full information maximum likelihood. In order to determine which correlation structure described the intra-individual correlation the best, Quasi-likelihood under the independence model criterion from analyses with different correlation structures were compared [28]. The autoregressive correlation structure showed the lowest value and was thus chosen. In order to study the changes in the amount of annual purchases of prescribed sedatives and anxiolytics, we applied repeated-measures Poisson regression analysis with generalized estimating equations estimation. In all analyses, trajectories were derived separately for the four groups. After examination of the time trends, the 9-year time window was divided into four distinct periods: “early pre-downsizing” (years -4 and -3), “late pre-downsizing” (-3 to -1), “peri-downsizing” (-1 to +1) and “post-downsizing” (+1 to +4). In order to investigate whether the groups changed their probabilities of purchases over time, odds ratios (OR) and their 95% confidence intervals (95% CI) were calculated contrasting prevalence of purchases during the first and the last 12-month period in each of the four time periods for each exposure group. Crude analyses, only adjusted for calendar time, were followed by analyses controlling for sociodemographic factors and previous sickness absence, added to the model as main effects. We further tested for differences in time trends between the exposed groups and the unexposed group within the four periods. See S1 Appendix for the SAS 9.4 scripts used for these analyses. We stratified the results by sex and age groups, respectively, to test for differences between men and women and across the age groups. Finally, in order to account for a health selection effect we stratified our sample by pre-downsizing sickness absence and conducted the analyses separately for employees with and without a previous sickness absence. Results Within this population-based Swedish cohort study of 2,305,795 employees, 915,461 individuals (40%) were defined as exposed to downsizing. The majority of them were still employed at the same workplace the year after the event (Table 1). Among leavers, 22% became unemployed while the rest changed their workplace. Compared to the other groups, the unemployed were generally younger, lower educated, more often living alone and had more often had previous sickness absence. 10.1371/journal.pone.0295383.t001Table 1Descriptive statistics by employment status following from downsizing.Sociodemographic factors from the year before the downsizing event and proportion of people with purchases of sedatives and anxiolytics across the studied period and average number of purchases made.Employment status after major downsizingUnemployedStayerChangerNot exposedn%(sd)n%(sd)n%(sd)n%(sd)82,518544,031288,9121,390,334Purchased any sedatives20.312.913.914.2Purchased any anxiolytics19.611.912.712.5Average number of purchases for sedatives2.8(14.8)1.2(8.1)1.2(8.2)1.4(9.3)Average number of purchases for anxiolytic1.8(11.0)0.7(5.6)0.7(5.9)0.8(6.4)Men42,87052.0292,55053.8153,58353.2715,96751.5Women39,64848.1251,48146.2135,32946.8674,36748.520–3427,12732.9128,77923.789,25330.9290,41220.935–4938,15146.2293,03553.9147,73851.1752,88654.250–5917,23920.9122,21722.5519,2118.0347,03625.0Primary education13,50116.457,87510.724,6828.6124,0008.9Secondary education51,89963.1307,76656.7150,32252.1675,06448.6Post-secondary education <3 years5,1346.236,5996.720,9137.396,6787.0Post-secondary education ≥ 3 years11,75914.3141,03326.092,67732.1492,92635.5Living with partner. children at home6,4847.948,4808.921,5417.5131,2379.4Living with partner. no children at home34,75342.1297,55454.7153,13353.0770,70155.4Living only with children at home9,80111.949,5009.126,7949.3124,6059.0Living alone31,48038.2148,49727.387,44430.3363,78926.2Living in big city24,03529.1187,99734.6119,88841.5535,32738.5Living in medium-sized city30,63837.1193,33035.596,33033.3492,45735.4Living small city/village27,84533.7162,70429.972,69425.2362,55026.1Sick leave previous 2 years24,41929.686,48415.948,24616.7228,87516.5Disability pension previous 2 years6,0337.38,9181.63,6761.331,4912.3 Descriptive statistics by employment status following from downsizing. Sociodemographic factors from the year before the downsizing event and proportion of people with purchases of sedatives and anxiolytics across the studied period and average number of purchases made. As shown in Table 1, a larger proportion of the changers belonged to the youngest age group, but in general purchases of psychotropic drugs and socio-demographic factors did not differ much between unexposed, stayers and changers. About 12% of them bought any prescribed anxiolytics during the studied period and the average person made less than 1 purchase across the nine 12-month periods. Among the unemployed however, 20% bought anxiolytics and the average person made almost 2 purchases. Purchases of sedatives were slightly more common than anxiolytics in all groups, but the same pattern was found when comparing prevalence across different groups. Purchases of prescribed psychotropic drugs in relation to a downsizing event Fig 2 presents trajectories of the estimated prevalence of purchasing prescribed anxiolytics in the 9-year time window, adjusted for calendar year, socio-demographic factors and previous sickness absence. Stayers, changers and non-exposed had a lower prevalence and a relatively stable pattern compared to the unemployed. However, when contrasting the odds of purchases of prescribed anxiolytics over time within groups, stayers appeared to have an increasing prevalence in the late pre- (OR 1.03 95% CI 1.01, 1.06), peri- (OR 1.05 95% CI 1.03, 1.08) and post-downsizing phase (OR 1.04, 95% CI 1.00, 1.07), see Table 2. The trend was also more pronounced than for unexposed in the peri- and post-downsizing phase. The * sign in Table 2 indicates when test result displayed significant trend difference between exposed and unexposed employees. Although the unemployed had a higher prevalence of purchasing prescribed anxiolytics across the whole period, they had a declining trend. However, the decrease seemed to be interrupted by the downsizing event as the prevalence increased with about 8% (OR 1.08, 95% CI 1.03, 1.14) during the late pre-downsizing period and then continued to decrease again in the peri-downsizing period (OR 0.84, 95% CI 0.80, 0.88) and the post-downsizing period (OR 0.91, 95% CI 0.85, 0.97), all of which were different from the pattern among unexposed. No clear trend was evident for the changers. The same analyses were performed for sedatives, showing relatively similar patterns. However, changers seemed to have larger increases in prevalence during the late pre- and post-downsizing phases compared to the unexposed, but less pronounced during peri-downsizing (Table 2 and Fig 3). Prevalence of purchased prescribed anxiolytics by employment status (%). Adjusted for sociodemographic factors and previous sickness absence, with 95% CI. Prevalence of purchased prescribed sedatives by employment status (%). Adjusted for sociodemographic factors and previous sickness absence, with 95% CI. 10.1371/journal.pone.0295383.t002Table 2Odds ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% confidence interval (CI) in relation to a downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing.Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models.Early pre-downsizingLate pre-downsizingPeri-downsizingPost-downsizing‘-3 to -4’d‘-1 to -3’e‘+1 to -1’f‘+4 to +1’gOR95% CIOR95% CIOR95% CIOR95% CI Anxiolytics Crudeb: Not exposed 1.000.98, 1.011.000.99, 1.021.021.00, 1.030.990.98, 1.01 Unemployed 0.920.87, 0.971.040.99, 1.100.810.77, 0.850.860.81, 0.92 Stayer 1.000.97, 1.021.031.00, 1.061.041.02, 1.071.020.98, 1.05 Changer 1.000.96, 1.041.020.98, 1.050.990.96, 1.031.010.97, 1.05Adjustedc: Not exposed 1.000.98, 1.011.010.99, 1.021.021.00, 1.030.990.98, 1.01 Unemployed 0.94*0.90, 1.001.08*1.03, 1.140.84*0.80, 0.880.91*0.85, 0.97 Stayer 1.010.98, 1.041.031.01, 1.061.05*1.03, 1.081.04*1.00, 1.07 Changer 1.010.97, 1.051.030.99, 1.071.000.97, 1.041.030.99, 1.07 Sedatives Crudeb: Not exposed 0.990.98, 1.001.011.00, 1.021.000.99, 1.010.990.98, 1.01 Unemployed 0.920.88, 0.960.960.91, 1.000.790.76, 0.820.840.79, 0.89 Stayer 0.970.95, 0.991.021.00, 1.051.031.00, 1.051.010.98, 1.04 Changer 0.970.94, 1.001.020.99, 1.050.960.93, 0.981.010.98, 1.05Adjustedc: Not exposed 1.021.00, 1.031.061.05, 1.071.051.03, 1.061.061.04, 1.08 Unemployed 0.970.93, 1.011.04*0.99, 1.090.85*0.81, 0.890.95*0.89, 1.00 Stayer 1.000.98, 1.031.081.05, 1.111.09*1.06, 1.111.101.07, 1.13 Changer 1.000.97, 1.031.08*1.05, 1.111.01*0.99, 1.041.11*1.07, 1.15a) * Is used as an indication for a period where the exposed group differ from the unexposed according to contrasting odds ratio testb) Crude model, only adjusted for calendar yearc) Adjusted model, adjustment for calendar year, sociodemographic factors and previous sickness absenced) The prevalence at time -3 is compared to prevalence at time -4 before downsizinge) The prevalence at time -1 is compared to prevalence at time -3 before downsizingf) The prevalence at time +1 after downsizing is compared to prevalence at time -1 before downsizingg) The prevalence at time +4 is compared to prevalence at time +1 after downsizing Odds ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% confidence interval (CI) in relation to a downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing. Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models. a) * Is used as an indication for a period where the exposed group differ from the unexposed according to contrasting odds ratio test b) Crude model, only adjusted for calendar year c) Adjusted model, adjustment for calendar year, sociodemographic factors and previous sickness absence d) The prevalence at time -3 is compared to prevalence at time -4 before downsizing e) The prevalence at time -1 is compared to prevalence at time -3 before downsizing f) The prevalence at time +1 after downsizing is compared to prevalence at time -1 before downsizing g) The prevalence at time +4 is compared to prevalence at time +1 after downsizing The average number of purchases of anxiolytics among users, S1 Fig, was higher for unemployed compared to the unexposed during the late pre-downsizing period, when adjusted for demographics and previous sickness absence. As in the main analysis, compared to the unexposed, unemployed increased the number of purchases of anxiolytics during late pre-downsizing but then decreased to the end of follow up. The stayers continued to increase their number of purchases in the peri- (Rate Ratio (RR) 1.08, 95% CI 1.04, 1.13) and the post-downsizing period (RR 1.09, 95% CI 1.03, 1.15) more than the unexposed, see S1 Table. A similar pattern was observed for stayers and unemployed when looking at the number of purchased sedatives, while the changers seemed to increase more than the unexposed during peri- and post downsizing (‘+4 vs -1’), see S2 Fig. Stratified analysis was performed by sex, showing similar patterns for all psychotropic drugs for men and women (see S3 and S4 Figs). Further, we stratified the analysis by age group yielding similar patterns across age groups and drug type, although the prevalence from the peri-downsizing phase and onwards declined more in the youngest age group (S5 and S6 Figs). Purchases of prescribed psychotropic drugs in relation to a downsizing event taking previous sickness absence into account In Table 3, results from adjusted analysis are presented, stratified by previous sickness absence. All groups with previous sickness absence increased their prevalence of purchases of anxiolytics before the event, see Fig 4. Moreover, unemployed (OR 1.25, 95% CI 1.17, 1.34) increased their purchases late pre-downsizing more than the non-exposed (OR. 1.18 95% CI 1.15, 1.21). During the peri-downsizing period, and post-downsizing (‘+4 vs -1’) the unemployed decreased their prevalence of purchasing anxiolytics more compared to the unexposed. Although the stayers and changers increased their odds of any purchases during the late pre-downsizing period, see Fig 4, this increase did not differ from the unexposed. In contrast to the unexposed, changers did not decrease their purchases of anxiolytics post-downsizing. For average number of purchases of anxiolytics all the exposed groups increased more than the unexposed during the late pre-downsizing phase (S7 Fig). Prevalence of purchased prescribed anxiolytics among people with a previous sickness absence. Adjusted for sociodemographic factors and with 95% CI. 10.1371/journal.pone.0295383.t003Table 3Odds ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% confidence interval (CI) in relation to the downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing, and previous sickness absence.Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models.Early pre-Late pre-Peri-downsizingPost-downsizing‘+4 vs -1’gdownsizing ‘-3 vs -4’cdownsizing ‘-1 vs -3’d‘+1 vs -1’e‘+4 vs +1’fOR95% CIOR95% CIOR95% CIOR95% CI Anxiolytics b) Previous sickness absence Not exposed 1.091.07, 1.121.181.15, 1.210.800.78, 0.820.940.91, 0.96 Unemployed 1.050.98, 1.121.25*1.17, 1.340.73*0.69, 0.780.930.85, 1.01* Stayer 1.101.05, 1.151.261.20, 1.310.810.78, 0.850.970.92, 1.02 Changer 1.111.05, 1.181.251.18, 1.320.770.74, 0.821.01*0.94, 1.08 NO previous sickness absence Not exposed 0.930.91, 0.950.870.85, 0.881.251.22, 1.271.041.02, 1.07 Unemployed 0.80*0.74, 0.880.810.73, 0.881.091.00, 1.180.890.81, 0.99 Stayer 0.950.92, 0.990.880.85, 0.911.271.23,1.311.091.05, 1.13* Changer 0.940.90, 0.990.870.83, 0.921.211.16, 1.271.051.00, 1.10Sedatives b) Previous sickness absence Not exposed 1.111.09, 1.121.241.21, 1.260.850.84, 0.870.990.97, 1.02 Unemployed 1.040.99, 1.101.21*1.14, 1.280.78*0.74, 0.820.92*0.85, 0.99* Stayer 1.091.05, 1.131.32*1.28, 1.380.860.83, 0.891.020.97, 1.07 Changer 1.121.07, 1.171.33*1.27, 1.400.79*0.76, 0.831.05*0.99, 1.11 NO previous sickness absence Not exposed 0.950.94, 0.970.930.91, 0.941.221.20, 1.241.111.09, 1.13 Unemployed 0.850.79, 0.910.760.70, 0.821.00*0.92, 1.081.000.91, 1.10 Stayer 0.950.92, 0.980.920.89, 0.951.28*1.24, 1.311.161.12, 1.20* Changer 0.930.90, 0.970.910.88, 0.951.211.17, 1.261.16*1.11, 1.21a) a as an indication for a period where the exposed group differ from the unexposed according to contrasting odds ratio testb) Adjusted model, adjustment for calendar year, sociodemographic factors and previous sickness absencec) The prevalence at time -3 is compared to prevalence at time -4 before downsizingd) The prevalence at time -1 is compared to prevalence at time -3 before downsizinge) The prevalence at time +1 after downsizing is compared to prevalence at time -1 before downsizingf) The prevalence at time +4 is compared to prevalence at time +1 after downsizingg) The prevalence at time +4 after downsizing is compared to prevalence at time -1 before downsizing Odds ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% confidence interval (CI) in relation to the downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing, and previous sickness absence. Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models. a) a as an indication for a period where the exposed group differ from the unexposed according to contrasting odds ratio test b) Adjusted model, adjustment for calendar year, sociodemographic factors and previous sickness absence c) The prevalence at time -3 is compared to prevalence at time -4 before downsizing d) The prevalence at time -1 is compared to prevalence at time -3 before downsizing e) The prevalence at time +1 after downsizing is compared to prevalence at time -1 before downsizing f) The prevalence at time +4 is compared to prevalence at time +1 after downsizing g) The prevalence at time +4 after downsizing is compared to prevalence at time -1 before downsizing Looking at the corresponding figures for people without previous sickness absence (Fig 5 and S8 Fig), all groups had a lower prevalence of purchasing prescribed anxiolytics before the event followed by a slight increase from one year before the event and onwards. In the early pre-downsizing period the unemployed had a larger decrease than the unexposed. Stayers increased their odds of purchasing prescribed anxiolytics somewhat more than the unexposed from one year before the event up to four years after while changes among unemployed and changers did not differ from that of unexposed according to the contrast test. Prevalence of purchased prescribed anxiolytics among people without a previous sickness absence. Adjusted for sociodemographic factors and with 95% CI. A similar pattern was observed when studying purchases of sedatives among people with and without previous sickness absence, see S9–S12 Figs. Results for stayers and changers with a prior sickness absence showed a stronger increase of sedatives during the late pre-downsizing phase compared to the unexposed, whereas the unemployed had less of an increase. More pronounced decreasing trends for changers and unemployed were found during the peri-downsizing phase, than for the unexposed. Changers with previous sickness absence increased their purchases more than the unexposed during the post-downsizing period, whereas the unemployed decreased more in this period. Stayers without previous sickness absence increased their purchases of sedatives more than the unexposed from one year before downsizing and onwards (+4 vs -1) and in particular the peri-downsizing phase. Changers increased their prevalence more than the unexposed post downsizing. Discussion We found a significant, albeit weak association between exposure to downsizing and prevalence of anxiolytic and sedative drugs. The results indicated that the use of these psychotropic drugs increased most for stayers during and after downsizing. The different time trends in purchases of psychotropic drugs between exposed and unexposed employees, during certain phases, indicated that downsizing might entail treatment of mental health problems. During the period prior to the downsizing event, often referred to as the anticipation phase, it was primarily the unemployed and the changer groups that seemed to experience an increase in psychotropic drug purchases. The findings are in accordance with previous studies showing that the anticipation phase before a job change or unemployment has predominantly detrimental health effects [29–31]. This phase might be characterized by high levels of uncertainty about the future causing stress reactions, poor self-rated health, poor psychological wellbeing and emotional exhaustion [30, 32–34]. In addition, previous studies have shown that the time before an event is characterized by poorer perceived work environment in terms of work load and relations to co-workers and managers [3, 33, 35]. While the prevalence of purchasing psychotropic drugs decreased among the unemployed it increased among those who stayed within the organization after a downsizing. This could be a result of an increased work load [33], and feelings of guilt over colleagues who were laid off [8]. Downsizing may also entail a pressure to modify jobs in ways that lead to lowered skill discretion, decreased decision authority and participation in decision making, and reduced work predictability [36]. The decreasing pattern among the unemployed from the peri-downsizing period and onwards might reflect a situation characterized by relief from the major stressor of uncertainty [37]. It might also reflect less need for sedatives and anxiolytics in order to cope and perform at work. According to a previous study which followed employees in Sweden from two years before to two years after an organizational downsizing, employees exposed to downsizing had higher odds of purchasing prescribed antidepressant compared to employees unexposed to downsizing [10]. Adding to the results of that study, we also found that during the pre-downsizing period the changers and unemployed increased their purchases of psychotropics in comparison to unexposed. However, while we observed a marked drop in sedative and anxiolytic purchases during the peri-period particularly among the unemployed, when compared to the unexposed, in the study by Magnusson et al. [10] the trends in antidepressant purchases for changers and unemployed during this period were more similar to that of the unexposed. The limited differences across the studies could be influenced by the high level of comorbidity between anxiety, sleep problems and depressive symptoms, the multiple indications that can exist for a certain type of psychotropic medication, and further that anxiolytics and sedatives can be used as pro re nata medications for insomnia, agitation or anxiety while treatments for depression are recommended to be more long-term. Sedatives and anxiolytics purchases may therefore capture some of the more subthreshold symptoms of poor mental health which may not have been captured in the study by Magnusson et al. The results further underscore the necessity of considering the various employment situations that employees may experience in connection with a downsizing, which in turn may impact differently on their mental health. In order to address the possibility that the results were explained by health selection we stratified our sample by previous sickness absence. Bernstrom [38] studied whether stages of job change could be reflected in sickness absence and found that two years before leaving an organization the odds of sickness absence increased and then dropped again when the subjects entered a new organization. Our results on psychotropic drugs show a similar pattern in most cases, suggesting that the period before leaving one’s job is detrimental in terms of feelings of anxiety and sleeping problems. After stratification by sickness absence during the two years before the event the stayers and changers with previous sickness absence had a higher increase in prevalence of purchasing sedatives compared to the unexposed group during the years before the event. The same was observed for anxiolytics, but only among the unemployed. Among those without previous sickness absence, stayers increased their prevalence during the peri- and post-downsizing period compared to the unexposed group. Thus even when taking previous sickness absence into account, being exposed to a downsizing and subsequently remain in paid work was associated with a higher increase in prevalence of purchasing psychotropic drugs compared to not being exposed. Strengths and limitations This study is based on a total population of employed Swedes with virtually no missing data, thus the sample is highly representative of the Swedish work force. The Swedish National Prescribed Drug Register contains information on all prescribed drugs dispensed at a Swedish pharmacy and thus has a good coverage of purchases of the drugs in focus in the present study. Information on redeemed prescribed sedatives and anxiolytics from several years before and after exposure to downsizing were utilized, making it possible to capture changes within different phases of the downsizing process. By examining different types of drugs this study can also contribute to a better understanding of potential short- and long-term effects of downsizing. Due to the long period with available data we were able to utilize exposure to downsizing occurring in four different 12-month periods, making the results less sensitive to conditions of the labor market in one specific year. Hence, the associations between downsizing and purchases of psychotropic drugs are not likely to be influenced solely by the recession in 2008, although more major downsizing events occurred shortly after the economic downturn. Furthermore, dividing the exposed group into different categories based on their employment situation the year after downsizing made it possible to investigate the heterogeneity in purchases among different exposed groups. Since information on exposure and outcome is based on register data, this study should furthermore not be influenced by, e.g., recall bias and common method bias. However, using only register based information on downsizing infers a risk of misclassification. From the Statistics on Dynamics of Enterprises and Establishments (DEE) register we only know whether a workplace reduced their staff or not between two subsequent years but not whether the person we defined as being exposed to downsizing was directly affected by staff reductions at that workplace. The downsizing could have been restricted to specific units at the workplace. On the contrary there might be people who have been classified as non-exposed although they might work in a unit heavily targeted with major staff reductions. Employees classified as unexposed could also have been exposed to minor downsizing. This type of misclassification would result in an underestimation of any effect of downsizing on mental health. Moreover, we have used the most commonly applied definition of major downsizing, but according to our knowledge, a standard definition of major downsizing is lacking. Although previous studies have shown stronger associations between major downsizing and health than for minor downsizing [1], further work may be needed on degree of downsizing and health effects. Regarding purchases of prescribed sedatives and anxiolytics, a couple of limitations are worth noting. Studying the number of purchases made is somewhat crude as it does not capture the variation in dose-levels, meaning that differences in defined daily dosages are not detected. However, results regarding the number of purchases per person did not differ much from the trends of any purchases made and the problem of non-adherence would persist even if a more detailed measure was applied. Furthermore, the people captured in this study might be what Last and Adelaide call the tip of the iceberg [39]. Not all people with sleep disorders or anxiety will seek health care and not all prescribed medication will be redeemed. We also know that health care utilization in relation to need varies between socioeconomic groups [40], and gender differences in reporting and handling mental disorders has been observed [41, 42]. However, health care in Sweden is largely tax-funded providing relatively equal access to health-care services irrespective of employment status. Conclusion To conclude, this study supports an association between downsizing and purchases of prescribed psychotropic drugs. The results indicating an increase in psychotropic drug purchases prior to the downsizing event among changes and those who became unemployed after the downsizing implies that the anticipation-phase is a stressful time in the downsizing process for the exposed employees. The results however, suggested an even more prominent increase psychotropic drug purchases across the period of downsizing and the following years among those who continued to work in the same workplace, i.e., the stayers. This also implies that an organizational downsizing can have long-term consequences on mental health for those who stay in the organization, which did not appear to be attributed to health selection, indicating a need for preventive measures. Supporting information Analysis script for the GEE method. (DOCX) Click here for additional data file. Average number of purchases of anxiolytics by employment status after downsizing. Adjusted for sociodemographic factors and previous sickness absence, with 95% CI. (DOCX) Click here for additional data file. Average number of purchases of sedatives by employment status after downsizing. Adjusted for sociodemographic factors and previous sickness absence, with 95% CI. (DOCX) Click here for additional data file. Prevalence of purchased prescribed sedatives by sex (%). Adjusted for sociodemographic factors and previous sickness absence. (DOCX) Click here for additional data file. Prevalence of purchased prescribed anxiolytics by sex (%). Adjusted for sociodemographic factors and previous sickness absence. (DOCX) Click here for additional data file. Prevalence of purchased prescribed sedatives by age groups (%). Adjusted for sociodemographic factors and previous sickness absence. (DOCX) Click here for additional data file. Prevalence of purchased prescribed anxiolytics by age groups (%). Adjusted for sociodemographic factors and previous sickness absence. (DOCX) Click here for additional data file. Average number of purchases of anxiolytics by employment status after downsizing, among individuals with prior sick leave. Adjusted for sociodemographic factors, with 95% CI. (DOCX) Click here for additional data file. Average number of purchases of anxiolytics by employment status after downsizing, among individuals without prior sick leave. Adjusted for sociodemographic factors, with 95% CI. (DOCX) Click here for additional data file. Prevalence of purchased prescribed sedatives by employment status after downsizing, among individuals with prior sick leave. Adjusted for sociodemographic factors, with 95% CI. (DOCX) Click here for additional data file. Average number of purchases of sedatives by employment status after downsizing, among individuals with prior sick leave. Adjusted for sociodemographic factors, with 95% CI. (DOCX) Click here for additional data file. Prevalence of purchased prescribed sedatives by employment status after downsizing, among individuals without prior sick leave. Adjusted for sociodemographic factors, with 95% CI. (DOCX) Click here for additional data file. Average number of purchases of sedatives by employment status after downsizing, among individuals without prior sick leave. Adjusted for sociodemographic factors, with 95% CI. (DOCX) Click here for additional data file. Rate ratios (RR) for purchases of prescription anxiolytics and sedatives and their 95% confidence interval (CI) in relation to a downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing. Statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models. (DOCX) Click here for additional data file. 11 Apr 2023 PONE-D-23-00866Downsizing and purchases of psychotropic drugs: a longitudinal study of stayers, changers and unemployedPLOS ONE Dear Dr. Blomqvist, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by May 26 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Ali B. Mahmoud, Ph.D. Academic Editor PLOS ONE Journal Requirements: When submitting your revision, we need you to address these additional requirements. 1. Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf" 2. In your Data Availability statement, you have not specified where the minimal data set underlying the results described in your manuscript can be found. PLOS defines a study's minimal data set as the underlying data used to reach the conclusions drawn in the manuscript and any additional data required to replicate the reported study findings in their entirety. All PLOS journals require that the minimal data set be made fully available. For more information about our data policy, please see http://journals.plos.org/plosone/s/data-availability. Upon re-submitting your revised manuscript, please upload your study’s minimal underlying data set as either Supporting Information files or to a stable, public repository and include the relevant URLs, DOIs, or accession numbers within your revised cover letter. For a list of acceptable repositories, please see http://journals.plos.org/plosone/s/data-availability#loc-recommended-repositories. Any potentially identifying patient information must be fully anonymized. Important: If there are ethical or legal restrictions to sharing your data publicly, please explain these restrictions in detail. Please see our guidelines for more information on what we consider unacceptable restrictions to publicly sharing data: http://journals.plos.org/plosone/s/data-availability#loc-unacceptable-data-access-restrictions. Note that it is not acceptable for the authors to be the sole named individuals responsible for ensuring data access. We will update your Data Availability statement to reflect the information you provide in your cover letter. 3. Please amend the manuscript submission data (via Edit Submission) to include author Alexanderson Kristina, Vahtera Jussi, Westerlund Hugo and Magnusson Hanson L. Linda. 4. We note that you have included the phrase “data not shown” in your manuscript. Unfortunately, this does not meet our data sharing requirements. PLOS does not permit references to inaccessible data. We require that authors provide all relevant data within the paper, Supporting Information files, or in an acceptable, public repository. Please add a citation to support this phrase or upload the data that corresponds with these findings to a stable repository (such as Figshare or Dryad) and provide and URLs, DOIs, or accession numbers that may be used to access these data. Or, if the data are not a core part of the research being presented in your study, we ask that you remove the phrase that refers to these data. 5. Please include captions for your Supporting Information files at the end of your manuscript, and update any in-text citations to match accordingly. Please see our Supporting Information guidelines for more information: http://journals.plos.org/plosone/s/supporting-information. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ********** 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ********** 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ********** 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ********** 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This is well written descriptive evidence that the study indicates that being exposed to downsizing is associated with increased use of sedatives and anxiolytics, before the event but especially thereafter for employees who stay in the organization. The major statistical approach is the use of the GEE with applied repeated-measures logistic regression analysis (OR and 95% CI).The most informative presentations are Table 3, trajectory Figures 2 to 5 and supplemental figures 1 to 8. The sample size is certainly adequate with the four major participating groups stratified accordingly. As noted above, the trends are described by the investigators. There is little or no inferential statistics except for the confidence intervals implying two sided statistical significance as seen in the text and in Table 3. Reviewer #2: This is an interesting and well-written paper on an important topic. 1) There is a special story about the paper: The paper is actually already published at Plos One (Reference #17) but was, according to the authors, retracted due to a coding mistake. Thus, this paper is the corrected version of the earlier paper, reference #17, that has been retracted. The authors describe the coding error and that this paper is a corrected version of the earlier paper in the end of the introduction. However, it does not say in the introduction that the earlier version was retracted, one only becomes aware of this, when looking up the reference in the reference list. Please make it clear, also in the introduction, that the previous paper was retracted. 2) Further, I suggest in the interest of full transparency, that you address both in the abstract and in the title that this is a corrected version of a previous paper that had been retracted. For example to change the title to: “Downsizing and purchases of psychotropic drugs: a longitudinal study of stayers, changers and unemployed. Corrected version of a retracted paper”. This is important, because right now the title of the retracted paper and the current paper is identical, which could be a source of confusion. 3) Strangely, when I looked up the previous paper in pubmed and on the Plos One Website, it does not say so that the paper was retracted. At least I could not find a notice on retraction there. Please clarify this. 4) I am uncertain how I should review this paper. As the previous paper went through peer-review and was accepted and published, and the current paper is a correction of a coding error, one could argue that the current paper should be automatically published after the coding error was corrected. However, since the journal sent me the paper and asked for a review, I did a normal review paper. But I am sure if this normal review is appropriate. 5) The seminal papers on downsizing and health of employees, who were affected by the downsizing in different ways (stayers, changers, unemployed) based on data from the great recession in Finland in the 1990s and published by Jussi Vahtera, Mika Kivimäki and others, need to be replicated in other settings (other countries and other time periods) and it is good that the current paper is doing this. 6) The first thing I was wondering about was why only anxiolytics and sedatives and not antidepressants? I agree, important to examine anxiolytics and sedatives but why did you leave out antidepressants? Was this because downsizing and antidepressants was already analyzed in the study by Magnusson Hanson et al 2016 (reference #10)? If this was the case, then please delineate in greater detail the results by Magnusson Hanson et al and compare them with your results. Because then, the whole picture of downsizing and use of psychotropic medication is distributed across two papers and it would be good if your paper synthesize the results from the two papers. 7) Why the cut-off point of >=18 for staff reduction? You write that this is “the most commonly used definition”, but is there any other reason why >=18 indicates major downsizing and staff reduction of 17% is not major? I suggest that you do sensitivity analyses with other cut-off points (e.g., >=13 or >=23) to examine if the results remain robust. It would be even better, if you could do dose-response analyses, comparing the risk of purchasing anxiolytics and sedatives for groups of no downsizing, minor downsizing and major downsizing. 8) With regard to supplementary analyses: Your outcome is prevalence of anxiolytics/sedatives purchase. Consider to analyze in addition incidence. Thus, to exclude everyone with a history of purchase before t minus 4 and then analyze incidence of purchase from t minus 4 to t plus 4. 9) With regard to the “changers”: Can you take into account, whether they changed to a job with a similar, higher or lower occupational grade? 10) With regard to “unemployed”. Can you take into account, how long the “unemployed” remained “unemployed” in subsequent years? 11) On page 16 you refer twice to “data not shown”. I suggest you show the data in Online Supplementary Material. For example, even though estimates were similar for men and women, showing the exact estimates stratified by sex would be informative, for example for future meta-analyses. Minor comments: 12) Page 23: “we only know if a workplace reduced their staff”. I am not a native English speaker, but it is my feeling that this should be “we only know whether a workplace reduced their staff”. 12) Page 23, last paragraph. Two sentences in a row start with “However”. Consider to change this. ********** 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 1 Jun 2023 Dear Editor and Reviewers, Thank you very much for taking the time to read and comment on our manuscript. As pointed out by one of the reviewers, this paper was first published in 2018, but an error was then discovered by the authors in 2020. Therefore, we promptly contacted PLOS One with new and corrected analyses together with a thorough description of the mistake and its implications for the results. We have repeatedly described both the error and its implication upon request from staff at PLOS One administrating this case. As Reviewer 2 also expresses, the paper has already undergone a peer review, based on which it was accepted. We have now tried to address the new reviewer comments where possible, but we have not changed or added any further analyses as we want this paper to resemble our original paper as much as possible, apart from the mistake. The rationale behind this is that the paper has already been cited and readers should easily be able to check what has been changed in this new and corrected version. With this in mind, please see our responses in connection to the reviewer’s comments below, and in the revised manuscript, which is enclosed both with tracked changes, and with all changes accepted. We sincerely hope that, after this long process of handling our case, you will find our reasoning and edits satisfying. On behalf of all the authors, Sandra Blomqvist Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 2. Has the statistical analysis been performed appropriately and rigorously? Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 3. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #1: Yes Reviewer #2: No ________________________________________ 4. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #1: Yes Reviewer #2: Yes ________________________________________ 5. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #1: This is well written descriptive evidence that the study indicates that being exposed to downsizing is associated with increased use of sedatives and anxiolytics, before the event but especially thereafter for employees who stay in the organization. The major statistical approach is the use of the GEE with applied repeated-measures logistic regression analysis (OR and 95% CI).The most informative presentations are Table 3, trajectory Figures 2 to 5 and supplemental figures 1 to 8. The sample size is certainly adequate with the four major participating groups stratified accordingly. As noted above, the trends are described by the investigators. There is little or no inferential statistics except for the confidence intervals implying two sided statistical significance as seen in the text and in Table 3. Thank you. Reviewer #2: This is an interesting and well-written paper on an important topic. 1) There is a special story about the paper: The paper is actually already published at Plos One (Reference #17) but was, according to the authors, retracted due to a coding mistake. Thus, this paper is the corrected version of the earlier paper, reference #17, that has been retracted. The authors describe the coding error and that this paper is a corrected version of the earlier paper in the end of the introduction. However, it does not say in the introduction that the earlier version was retracted, one only becomes aware of this, when looking up the reference in the reference list. Please make it clear, also in the introduction, that the previous paper was retracted. Thank you for reading our paper and yes, the paper has a special story to it. Regarding the status of the former version, we have followed the guidelines that we received from PLOS One. The procedure that PLOS One decided on, was that the corrected version should undergo yet another review and that the old paper should be replaced by the new (along with a retraction notice) as soon as the review process was over, given that it wasn’t too long. However, the process for PLOS One to find suitable reviewers took long and they decided to retract it anyway, thus the paper changed status after this new version was submitted, while awaiting reviewers. The formulations used in the paper concerning the old manuscript were those that the Plos One ethics team instructed us to use. However, we now suggest a slight revision of the formulation by the ethics team about the paper being retracted. Please see p. 4 in the version with tracked changes. The present study is the corrected version of a previously published version of this paper, now retracted, in which we found errors due to a coding mistake [17].” 2) Further, I suggest in the interest of full transparency, that you address both in the abstract and in the title that this is a corrected version of a previous paper that had been retracted. For example to change the title to: “Downsizing and purchases of psychotropic drugs: a longitudinal study of stayers, changers and unemployed. Corrected version of a retracted paper”. This is important, because right now the title of the retracted paper and the current paper is identical, which could be a source of confusion. As mentioned above, the ethics team at PLOS One instructed us exactly how the process concerning the retraction and resubmission of this paper should be communicated to future readers. However, if PLOS One so decided, we would have no problem to add the information suggested by the reviewer to the title. 3) Strangely, when I looked up the previous paper in pubmed and on the Plos One Website, it does not say so that the paper was retracted. At least I could not find a notice on retraction there. Please clarify this. We as authors neither fully understand nor agree with how our case have been handled. The paper was not retracted when this revised version was submitted even if we repeatedly pointed out to the journal that the paper was still available to read and cite, which of course was highly problematic. Therefore, we hope that the PLOS One ethics team, administrative team and/or editors can clarify this. 4) I am uncertain how I should review this paper. As the previous paper went through peer-review and was accepted and published, and the current paper is a correction of a coding error, one could argue that the current paper should be automatically published after the coding error was corrected. However, since the journal sent me the paper and asked for a review, I did a normal review paper. But I am sure if this normal review is appropriate. Thank you for spelling this out, and we agree. This manuscript is meant to be a corrected version of a previously peer reviewed paper and for transparency we believe that it should be minimally different from that paper as possible, apart from the mistake that we unfortunately made. 5) The seminal papers on downsizing and health of employees, who were affected by the downsizing in different ways (stayers, changers, unemployed) based on data from the great recession in Finland in the 1990s and published by Jussi Vahtera, Mika Kivimäki and others, need to be replicated in other settings (other countries and other time periods) and it is good that the current paper is doing this. Thank you, and we agree that this is important to do. 6) The first thing I was wondering about was why only anxiolytics and sedatives and not antidepressants? I agree, important to examine anxiolytics and sedatives but why did you leave out antidepressants? Was this because downsizing and antidepressants was already analyzed in the study by Magnusson Hanson et al 2016 (reference #10)? If this was the case, then please delineate in greater detail the results by Magnusson Hanson et al and compare them with your results. Because then, the whole picture of downsizing and use of psychotropic medication is distributed across two papers and it would be good if your paper synthesize the results from the two papers. Yes, this was because antidepressants were studied by Magnusson et. al. in 2016, and our intention with the present study was to build on that to examine temporal changes of different mental health conditions such as sleep and anxiety across the downsizing process, which potentially could occur earlier or precede depression. This was expressed very briefly in the discussion section but has now been elaborated slightly, See p. 21 and below. According to a previous study which followed employees in Sweden from two years before to two years after an organizational downsizing, employees exposed to downsizing had higher odds of purchasing prescribed antidepressant compared to employees unexposed to downsizing. [10] Adding to the results of that study, we also found that during the pre-downsizing period the changers and unemployed increased their purchases of psychotropics in comparison to unexposed. However, while we observed a marked drop in sedative and anxiolytic purchases during the peri-period particularly among the unemployed, when compared to the unexposed, in the study by Magnusson et. al. [10] the trends in antidepressant purchases for changers and unemployed during this period were more similar to that of the unexposed. The limited differences across the studies could be influenced by the high level of comorbidity between anxiety, sleep problems and depressive symptoms, the multiple indications that can exist for a certain type of psychotropic medication, and further that anxiolytics and sedatives can be used as pro re nata medications for insomnia, agitation or anxiety while treatments for depression are recommended to be more long-term. Sedatives and anxiolytics purchases may therefore capture some of the more subthreshold symptoms of poor mental health which may not have been captured in the study by Magnusson et. al. The results further underscore the necessity of considering the various employment situations that employees may experience in connection with a downsizing, which in turn may impact differently on their mental health. 7) Why the cut-off point of >=18 for staff reduction? You write that this is “the most commonly used definition”, but is there any other reason why >=18 indicates major downsizing and staff reduction of 17% is not major? I suggest that you do sensitivity analyses with other cut-off points (e.g., >=13 or >=23) to examine if the results remain robust. It would be even better, if you could do dose-response analyses, comparing the risk of purchasing anxiolytics and sedatives for groups of no downsizing, minor downsizing and major downsizing. We use it because it has become a de facto standard definition since it was used in the seminal paper by Vahtera et al. as well as by Magnusson et. al. 2016, which the current study builds on. To our understanding the cut off is arbitrary and does not have a clear theoretical underpinning, at least not discussed by Vahtera et. al. (1997). Others, including Vahtera et. al and Magnusson et. al. 2016, have shown previously that the association with sick leave spells, and antidepressant purchases, respectively seem to be stronger for major downsizing than minor downsizing. We could of course also have done this type of analysis but chose to focus on others, such as moderation by a person’s prior health status, age, sex etc. We suggest the following addition to the discussion though, to better clarify to reader our choice of cut off for the exposure. See p. 23-24. “Moreover, we have used the most commonly applied definition of major downsizing, but according to our knowledge, a standard definition of major downsizing is lacking. Although previous studies have shown stronger associations between major downsizing and health than for minor downsizing, [1] further work may be needed on degree of downsizing and health effects.” 8) With regard to supplementary analyses: Your outcome is prevalence of anxiolytics/sedatives purchase. Consider to analyze in addition incidence. Thus, to exclude everyone with a history of purchase before t minus 4 and then analyze incidence of purchase from t minus 4 to t plus 4. Incident purchases of anxiolytics and sedatives could indeed have been interesting. However, the Swedish prescribed drug register which includes all redeemed psychotropic drug prescriptions, was introduced in July 2005 and thus prevent us from using psychotropic drug medications further back in time, at timepoint - 5 years or earlier, as a way of controlling for prior mental health problems. As an alternative, we chose to handle potential reversed causation by prior mental health problems by stratifying on sick leave spells occurring two years prior to (or earlier) the downsizing. Furthermore, the outcome we used was odds ratio for purchasing prescribed psychotropics in a certain 12-month period, but we also contrasted the odds in one 12-month period with the odds in an earlier 12-month period within each group, and further against the unexposed group. This means that we analyzed change in purchases over time, not only prevalences in specific time periods. In addition, we also studied change in amount of purchases across time, in the same manner. This approach allows us to understand temporal dynamics in a way that would not be possible if we would only analyze incident cases. 9) With regard to the “changers”: Can you take into account, whether they changed to a job with a similar, higher or lower occupational grade? It could be possible but would require some fairly technical programming, and as it is slightly out of the scope for this paper, we feel that it is not motivated at this stage. 10) With regard to “unemployed”. Can you take into account, how long the “unemployed” remained “unemployed” in subsequent years? This is also possible and we did briefly look into how the length of the unemployment spell affected the trajectories of psychotropic drug purchase to better understand the group of unemployed. I recall that we found what others have presented before us, about job loss and mental health, namely that longer spells were associated with worse mental health than shorter spells. 11) On page 16 you refer twice to “data not shown”. I suggest you show the data in Online Supplementary Material. For example, even though estimates were similar for men and women, showing the exact estimates stratified by sex would be informative, for example for future meta-analyses. Thank you for this comment, we have now included the data as supplementary material instead and provide a note in the text where the reader can find it. Please see. p. 16. “Stratified analysis was performed by sex, showing similar patterns for all psychotropic drugs for men and women (see S3 and S4 Figs).” And p. 17 “For average number of purchases of anxiolytics all the exposed groups increased more than the unexposed during the late pre-downsizing phase (S7 Fig).” Minor comments: 12) Page 23: “we only know if a workplace reduced their staff”. I am not a native English speaker, but it is my feeling that this should be “we only know whether a workplace reduced their staff”. We have now changed to using “whether” instead of “if”. 12) Page 23, last paragraph. Two sentences in a row start with “However”. Consider to change this. Thanks for noticing that, we have varied our wording to create a better flow for the reader. ________________________________________ 6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #1: No Reviewer #2: No ________________________________________ Submitted filename: Response to reviewers.docx Click here for additional data file. 1 Sep 2023 PONE-D-23-00866R1Downsizing and purchases of psychotropic drugs: a longitudinal study of stayers, changers and unemployedPLOS ONE Dear Dr. Blomqvist, Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. Please submit your revised manuscript by Oct 16 2023 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file. Please include the following items when submitting your revised manuscript:A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'. If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols. We look forward to receiving your revised manuscript. Kind regards, Ali B. Mahmoud, Ph.D. Academic Editor PLOS ONE Journal Requirements: 1) Citation of the retracted paper (Introduction and Reference list): The text addressing the retraction in the Introduction text is suitable, but the citation of the retraction and original publication is not correct. The in-text citations in the Introduction should refer to both the retracted/original article and the retraction notice, which should be listed as follows in the References list: 17. Blomqvist S, Alexanderson K, Vahtera J, Westerlund H, Magnusson Hanson LL (2018) Downsizing and purchases of psychotropic drugs: A longitudinal study of stayers, changers and unemployed. PLoS ONE 13(8): e0203433. https://doi.org/10.1371/journal.pone.0203433 (Retracted) 18. Blomqvist S, Alexanderson K, Vahtera J, Westerlund H, Magnusson Hanson LL (2023) Retraction: Downsizing and purchases of psychotropic drugs: A longitudinal study of stayers, changers and unemployed. PLOS ONE 18(4): e0285004. https://doi.org/10.1371/journal.pone.0285004 When correcting this, please also update the citations and referencing for the articles currently listed as reference numbers 18+. 2) Analysis scripts: please could the scripts used for the analyses in the study by provided either in a Supplementary Information file or via a public repository. [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: No Reviewer #3: No ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: Dear Authors, Thank you for your response and for considering some of my comments. I understand that you could not consider all comments, because this paper is a special case (with its retraction history) and that you had been instructed by Plos One how to handle this. I do not have further comments or requests. Reviewer #3: Thank you for this opportunity to revisit your article concerning mental health and workplace downsizing. I agree with what both the authors and the reviewers stated in R1: This is a difficult paper to review as it has already undergone the process once. Also, I tend to agree with the authors that as the original paper with the error in it has already been cited, it would be best to refrain from making large changes to the paper. To more complicate things, I did not participate in the first round of peer reviews and most of the points I would have raised and were already made by the two reviewers participating in the first round and then adequately addressed by the authors. I will attempt to review the paper as requested, but with the previous round in mind. I think the authors have done a good job of describing the error in the original publication. I agree with what prior reviewers already suggested concerning the title, as it would be clearer to the reader if the retracted paper and the current version had separate titles. But this appears to be concern for the PLOS one team and not the authors. Several other points were also made in the previous round of reviews which I believe the authors have now adequately addressed, eg. that concerning the inclusion of antidepressants and the cut offs for workplace downsizing. I would have suggested to present results for both anxiolytics/sedatives and antidepressants from one set of data and analyses (addressed both together and separately), as well as running the models for both anxiolytics and sedatives together. However, the authors make a good case for their choice to to adhere to the original analyses. Minor concerns Table 3. The title is: "Odds Ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% Confidence Interval (CI) in relation to the downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing. Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models. All analysis are stratified by previous sickness absence." Would it be clearer if this was: "Odds Ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% Confidence Interval (CI) in relation to the downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing, and previous sickness absence. Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models." Discussion. The paper would have benefited from a brief discussion on the public health or clinical relevance of the results. What are the implications of the somewhat modest associations found here? But as you have already made multiple changes following reviewers suggestions and as the space is limited, I am happy with the discussion as is. In conclusions you write: "To conclude, this study supports an association between downsizing and purchases of prescribed psychotropic drugs. The association was observed before the event but especially prominent --" I'm not a native speaker, but I struggled with this section. Would something to the following effect be clearer to the reader: "This study supports an association between downsizing and purchases of prescribed psychotropic drugs. The association was especially prominent for the stayers before the event, and they also increased their purchases during and after downsizing. --- further implies that organizational downsizing can have long term mental health consequences for those who stay in the organization, indicating a need for health promoting measures." Altogether in the discussion, conclusions and abstract I sometimes found it difficult to say what your main conclusions for the leavers and the unemployed were. Perhaps these two groups could be included the conclusions, as well as add more detail on the main findings in the beginning of the discussion or the abstract? ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No ********** [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. 18 Oct 2023 Journal Requirements: 1) Citation of the retracted paper (Introduction and Reference list): The text addressing the retraction in the Introduction text is suitable, but the citation of the retraction and original publication is not correct. The in-text citations in the Introduction should refer to both the retracted/original article and the retraction notice, which should be listed as follows in the References list: 17. Blomqvist S, Alexanderson K, Vahtera J, Westerlund H, Magnusson Hanson LL (2018) Downsizing and purchases of psychotropic drugs: A longitudinal study of stayers, changers and unemployed. PLoS ONE 13(8): e0203433. https://doi.org/10.1371/journal.pone.0203433 (Retracted) 18. Blomqvist S, Alexanderson K, Vahtera J, Westerlund H, Magnusson Hanson LL (2023) Retraction: Downsizing and purchases of psychotropic drugs: A longitudinal study of stayers, changers and unemployed. PLOS ONE 18(4): e0285004. https://doi.org/10.1371/journal.pone.0285004 When correcting this, please also update the citations and referencing for the articles currently listed as reference numbers 18+. Thank you for the clarification of how to correctly cite the different versions. We have now updated the manuscript according to the requirements and further updated the subsequent refences in the list after adding reference no. 18, see. p. 4 in the introduction and the reference list on p. 27, (manuscript version w track changes) 2) Analysis scripts: please could the scripts used for the analyses in the study by provided either in a Supplementary Information file or via a public repository. We have now included the analysis scripts as Supplementary Information, see file: S1 Appendix. Analysis script for GEE methods And the following note included in the method section on p. 9: “See S1 Appendix for the SAS 9.4 scripts used for these analyses.” [Note: HTML markup is below. Please do not edit.] Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #2: All comments have been addressed Reviewer #3: All comments have been addressed ________________________________________ 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #2: Yes Reviewer #3: Yes ________________________________________ 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #2: Yes Reviewer #3: Yes ________________________________________ 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #2: No Reviewer #3: No ________________________________________ 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #2: Yes Reviewer #3: Yes ________________________________________ 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #2: Dear Authors, Thank you for your response and for considering some of my comments. I understand that you could not consider all comments, because this paper is a special case (with its retraction history) and that you had been instructed by Plos One how to handle this. I do not have further comments or requests. Thank you for taking the time to read and review our manuscript. Reviewer #3: Thank you for this opportunity to revisit your article concerning mental health and workplace downsizing. I agree with what both the authors and the reviewers stated in R1: This is a difficult paper to review as it has already undergone the process once. Also, I tend to agree with the authors that as the original paper with the error in it has already been cited, it would be best to refrain from making large changes to the paper. To more complicate things, I did not participate in the first round of peer reviews and most of the points I would have raised and were already made by the two reviewers participating in the first round and then adequately addressed by the authors. I will attempt to review the paper as requested, but with the previous round in mind. I think the authors have done a good job of describing the error in the original publication. I agree with what prior reviewers already suggested concerning the title, as it would be clearer to the reader if the retracted paper and the current version had separate titles. But this appears to be concern for the PLOS one team and not the authors. Thank you and we would also like to refer this issue about the title to the PLOS one team and how titles for retraction and resubmissions are normally dealt with. Several other points were also made in the previous round of reviews which I believe the authors have now adequately addressed, eg. that concerning the inclusion of antidepressants and the cut offs for workplace downsizing. I would have suggested to present results for both anxiolytics/sedatives and antidepressants from one set of data and analyses (addressed both together and separately), as well as running the models for both anxiolytics and sedatives together. However, the authors make a good case for their choice to to adhere to the original analyses. Yes, we acknowledge that improvement of the paper can be done and these are all good suggestions. However, as noted already, for this particular case we would like to stay as close to the original version as possible and not introduce new types of analysis since the old version has already been cited. Minor concerns Table 3. The title is: "Odds Ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% Confidence Interval (CI) in relation to the downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing. Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models. All analysis are stratified by previous sickness absence." Would it be clearer if this was: "Odds Ratios (OR) for purchases of prescription anxiolytics and sedatives and their 95% Confidence Interval (CI) in relation to the downsizing event, comparing changes over time within groups in analyses stratified by downsizing and employment status after downsizing, and previous sickness absence. Any statistically significant differences between exposed and not exposed are expressed with * in mutually adjusted models." Yes, thank you, this reads a lot smoother. We have now updated the title according to your suggestion. See page 18, manuscript version w track changes. Discussion. The paper would have benefited from a brief discussion on the public health or clinical relevance of the results. What are the implications of the somewhat modest associations found here? But as you have already made multiple changes following reviewers suggestions and as the space is limited, I am happy with the discussion as is. In conclusions you write: "To conclude, this study supports an association between downsizing and purchases of prescribed psychotropic drugs. The association was observed before the event but especially prominent --" I'm not a native speaker, but I struggled with this section. Would something to the following effect be clearer to the reader: "This study supports an association between downsizing and purchases of prescribed psychotropic drugs. The association was especially prominent for the stayers before the event, and they also increased their purchases during and after downsizing. --- further implies that organizational downsizing can have long term mental health consequences for those who stay in the organization, indicating a need for health promoting measures." We see your point but we also believe that the suggestion points in a slightly different direction than what we have intended. The text alteration seems to suggest that stayers were particularly affected prior to the event but this was not the case for this group, they were rather affected during and after the event- although some effect seemed to exist prior to the event too (mostly for those with a previous sickness absence). However, our original formulation was not optimal either. We therefore suggest that it is worded in following way instead (on page 24-25 in the manuscript w tracked changes): “To conclude, this study supports an association between downsizing and purchases of prescribed psychotropic drugs. The results indicating an increase in psychotropic drug purchases prior to the downsizing event among changes and those who became unemployed after the downsizing implies that the anticipation-phase is a stressful time in the downsizing process for the exposed employees. The results however, suggested an even more prominent increase psychotropic drug purchases across the period of downsizing and the following years among those who continued to work in the same workplace, i.e., the stayers. This also implies that an organizational downsizing can have long-term consequences on mental health for those who stay in the organization, which did not appear to be attributed to health selection, indicating a need for preventive measures.” Altogether in the discussion, conclusions and abstract I sometimes found it difficult to say what your main conclusions for the leavers and the unemployed were. Perhaps these two groups could be included the conclusions, as well as add more detail on the main findings in the beginning of the discussion or the abstract? See our suggestion above, where we’ve tried to address this issue by more explicitly include how unemployed and changers were affected in the overall conclusion. We also revised the abstract slightly to be more explicit about the changers and the unemployed, i.e., the leavers. See the abstract and below: “This study indicates that being exposed to downsizing is associated with increased use of sedatives and anxiolytics, before the event among those who leave, but especially thereafter for employees who stay in the organization.” We further added the following sentence in the discussion section concerning the most important findings for these two groups, which is placed as the second paragraph in the discussion section, p. 20 “During the period prior to the downsizing event, often referred to as the anticipation phase, it was primarily the unemployed and the changer groups that seemed to experience an increase in psychotropic drug purchases. The findings are in accordance with previous studies showing that the anticipation phase before a job change or unemployment has predominantly detrimental health effects [29-31].” ________________________________________ 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #2: No Reviewer #3: No ________________________________________ [NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.] While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step. Submitted filename: Rebuttal letter PLOS One.docx Click here for additional data file. 22 Nov 2023 Downsizing and purchases of psychotropic drugs: a longitudinal study of stayers, changers and unemployed PONE-D-23-00866R2 Dear Dr. Blomqvist, We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements. Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication. An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org. If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org. Kind regards, Ali B. Mahmoud, Ph.D. Academic Editor PLOS ONE Additional Editor Comments (optional): Reviewers' comments: Reviewer's Responses to Questions Comments to the Author 1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation. Reviewer #3: All comments have been addressed ********** 2. Is the manuscript technically sound, and do the data support the conclusions? The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented. Reviewer #3: Yes ********** 3. Has the statistical analysis been performed appropriately and rigorously? Reviewer #3: Yes ********** 4. Have the authors made all data underlying the findings in their manuscript fully available? The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified. Reviewer #3: Yes ********** 5. Is the manuscript presented in an intelligible fashion and written in standard English? PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here. Reviewer #3: Yes ********** 6. Review Comments to the Author Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters) Reviewer #3: I have no further comments. The authors make a strong case in arguing for publishing the revised version without making more major changes. ********** 7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files. If you choose “no”, your identity will remain anonymous but your review may still be made public. Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy. Reviewer #3: No ********** 28 Nov 2023 PONE-D-23-00866R2 Downsizing and purchases of psychotropic drugs: a longitudinal study of stayers, changers and unemployed Dear Dr. Blomqvist: I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department. If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org. If we can help with anything else, please email us at customercare@plos.org. Thank you for submitting your work to PLOS ONE and supporting open access. Kind regards, PLOS ONE Editorial Office Staff on behalf of Dr. Ali B. Mahmoud Academic Editor PLOS ONE